Natural History of Autosomal Dominant Hearing Loss

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Study ID
NCT04501081
Status
Recruiting
Apply to this trial

Conditions

  • Hearing Loss

Eligibility Criteria

Sex
ALL
Age
3 Years - 99 Years
Healthy Volunteers
Accepted

Study Details

Background: Hereditary hearing loss is one of the most common sensory disabilities affecting newborns. The main options for people with hereditary hearing loss are hearing aids and cochlear implants. Both options have their limitations and do not restore biological hearing. Researchers want to learn if gene editing might be a treatment option. Objective: To understand the genes that cause non-syndromic autosomal dominant hearing loss (DFNA) in people with DFNA as well as their family members. Eligibility: People age 3 99 who have DFNA, affected family members of enrolled participants with DFNA, and unaffected family members of enrolled participants Design: Participants will be screened with a medical and hearing history. Their medical records will be reviewed. Participants will have hearing tests. They will wear headphones or earplugs. They will listen to tones, sounds, and words and may be asked to describe what they hear. Participants will have balance tests. For these, they will wear googles as they watch moving lights or as cold or warm air is blown into their ears. They will sit in a spinning chair in a quiet, dark booth. From a reclined position, they will raise their head while listening to clicking sounds. Participants will have blood drawn through a needle in the arm. Some blood will be used for gene testing. Some participants will have 2 skin biopsies. The skin will be washed, and a numbing medicine will be injected. Two small pieces of skin will be removed. Participants may have a physical exam. Participation will last for up to 20 years. Participants may give medical updates once a year.

Key Dates

Start date
Feb 9, 2021
Status verified
May 2026
Primary completion
Aug 21, 2029
Completion
Aug 21, 2029

Study Design

Enrollment
1,100 participants (estimated)

Arms

  • Arm: 1
    DFNA patients and their family members (affected)
  • Arm: 2
    DFNA patients and their family members (unaffected)

Primary Outcome Measure

Determine if genome editing could be applied to modify mutations in primary or immortalized cultured fibroblasts from patients with non-syndromic autosomal dominant hearing loss. [ Time Frame: Ongoing ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
National Institutes of Health Clinical CenterBethesdaMaryland20892
For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
[email protected]
800-411-1222

Find similar trials in Bethesda, MD

By research site
National Institutes of Health Clinical Center· Bethesda, MD

Related Studies